A Role for Immunotherapy in Patients with Concomitant KRAS and KEAP1/STK11/p53 Mutations

Video

The panel explains their approaches to treating patients with mutated NSCLC with immunotherapy.

Related Videos
Ashish Saxena, MD, PhD
Video 10 - "SELECT Trial & DECISION Trial Outcomes and Lessons Learned"
Video 9 - "Identifying RAI-Refractory Disease: A Key Aspect of DTC Management"
Video 18 - "Future Perspectives and Unmet Needs in Renal Cell Carcinoma"
Video 17 - "Nivolumab Plus Cabozantinib in Non–Clear Cell RCC"
Eric Vallieres, MD, FRCSC
Benjamin Levy, MD
Video 16 - "Trajectory of Evolving HCC Treatment Landscape"